Zymeworks Inc.
ZYMENYSETrackedHealth CareBiotechnology
Public exchange feeds are not currently returning active trading data for Zymeworks Inc. (ZYME). This company may be delisted, bankrupt, acquired, or halted. To preserve data integrity, prices are never displayed as $0.00. Sourced ESG ratings and sustainability disclosures remain cataloged below.
- Coverage
- Coverage universe Identity published; no third-party ESG observation yet.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Market data unavailableObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Market data unavailable
Massive Stock Widgets has not returned a current, verifiable snapshot for Zymeworks Inc. (nyse:ZYME). Check again later.
Company Profile & Business Model Overview
Zymeworks Inc. (NASDAQ: ZYME) is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates, and managing a portfolio of licensed healthcare assets. The company advances oncology and other therapeutic candidates while partnering and licensing certain assets to third parties. Headquartered in Vancouver, British Columbia, Zymeworks operates globally with clinical programs and licensed products contributing to its scale.
Sustainability Strengths & Catalysts (Pros)
- Robust biologics platform: Zymeworks has engineered multifunctional antibody platforms (e.g., Azymetric and EFECT) enabling development of differentiated therapeutics, which can improve targeting precision and potentially reduce off-target effects relativ
- Partnerships and licensing diversify risk: The company manages licensed healthcare assets and has entered collaborations that distribute development and commercialization risk, which can enhance financial resilience and continuity of patient access to the
- Clinical-stage innovation focus: Active clinical pipelines in oncology and other indications demonstrate ongoing R&D investment in treatments for serious diseases, aligning corporate activity with significant public health needs.
Material Risks & Governance Concerns (Cons)
- Clinical and development risk: As a clinical-stage biopharma, Zymeworks faces high technical and regulatory failure risk for its candidates, which can lead to stranded assets, layoffs, or supply disruptions affecting stakeholders.
- Limited commercial revenue diversification: Reliance on licensing deals and future commercialization of a small number of assets concentrates financial and operational risk, potentially affecting long-term sustainability and investor returns if key progra
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
MSCI and Sustainalytics ratings shown side by side, never blended into a single score.
Third-party ratings
Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Valuation metrics for this profile. Market cap is taken from the delayed market quote above.
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Zymeworks Inc. (ZYME)'s ESG rating and sustainability score?
Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Zymeworks Inc. (ZYME). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Is Zymeworks Inc. considered an ESG leader or laggard in Health Care?
Independent benchmark status for Zymeworks Inc. is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for Zymeworks Inc.?
Key material risks for Zymeworks Inc. include: Clinical and development risk: As a clinical-stage biopharma, Zymeworks faces high technical and regulatory failure risk for its candidates, which can lead to stranded assets, layoffs, or supply disruptions affecting stakeholders.; Limited commercial revenue diversification: Reliance on licensing deals and future commercialization of a small number of assets concentrates financial and operational risk, potentially affecting long-term sustainability and investor returns if key progra. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.